At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from the University of Cologne, Cologne, Germany, evaluates current and emerging approaches for managing patients with multiple myeloma, including drug sequencing and a clinical trial investigating lenalidomide, bortezomib, dexamethasone and elotuzumab as induction therapy for newly diagnosed patients.